Name of Mechanism of Contraindicati Adverse Nursing

Drug Action Indication on Side Effects Effects Responsibilitie

s
Mefenamic  Potent  Treatment of  salicylate h Stomach pain  Diarrhea  Encourage
Acid inhibitor of mild to severe ypersensiti Nausea  Long- the patient
500 mg 3x a prostaglandin discomfort in vity Vomiting term to report
day per synthesis in a short term Heartburn treatment the nurse if
orem vitro.  NSAID hy Constipation can lead she had
 Reducing persensitivi Rash enteritis dark stools
 Inhibition of distress and ty Dizziness or colitis. or sign of
cyclooxygena loss of blood Diarrhea  Urinary rashes so it
se (COX-1 during   Asthma retention will
and COX-2) menstrual  Visual discontinue
cycles.  Urticarial disturban the
 Has analgesic, ce medicine.
anti-  allergic  Encourage
inflammatory, reactions the patient
and to report if
antipyretic she feel
properties any sore
throat,
headache.
 Advice the
patient to
do not
drive or
participate
in
potentially
risk.

 Advice
the patient
to do not
breast-feed
without
consulting
a doctor
when
taking this
medication
.
 Evaluat
e the
patients
dehydratio
 n and
electrolyte
imbalance.
Cephalexin  beta-lactam  infections cau  Antimicrob  nausea  vaginal  Instruct
500 mg 3x a antibiotic sed ial  vomiting itching or the
day per by bacteria resistance  diarrhea discharge patient
orem  penicillin-  pneumonia  viral  abdominal  joint pain what
binding  respiratory infection discomfort  dizziness
medicatio
proteins and tract infection  Pregnancy.  Headach
inhibiting s  Renal e n with
cross-linking  infections of failure meals; if
of the the bone, skin,  Cephalosp her GI
peptidoglycan ears, , genital, orin hypers arises.
structure. and urinary ensitivity  Encourag
tract.   viral e the
 Inhibits DNA infection patient to
synthesis by  Breast-
inhibiting notify the
feeding
DNA gyrase nurse or
 inflammato
in susceptible ry bowel doctor if
gram negative disease she have
and gram trouble
positive breathing,
organisms
rash,
irregular
bleeding,
bruises
and
excessive
weakness
.
 Instruct
the
patient
that she
need to
avoid or
stop if she
still taking
cephalexi
n.
 Advice the
patient
 even she
is feeling
better, she
still need
to
complete
her cycle
of her
medicatio
n.
 Assess or
check the
patient if
the
infection
culture
and
sensitivity
checks
before
and
during
recovery if
the
bacteria is
not cured.
Senokot  Stimulant  Constipation o  Blockage  Abdomina  Vomiting  Evaluate
1 tablet at laxative f old age in the l pain the patient
bedtime per digestive  Muscle for
orem.  Irritating and  Constipation o tract  Nausea Cramps abdominal
stimulating f pregnancy distention,
intestinal cells  Crohn's  Diarrhea  Irregular occurrence
disease heartbeat of bowel
 Producing  Constipation d  Weakenin noises and
contractions ue to slow  Ulcerative g  Dizzines regular
in intestines passage colitis\ s bowel
through the movement
 Water influx colon  Inflammato  Decrease pattern.
to the ry colon d
intestines and  Irritable disease urination  Evaluate
bowel bowel the patients
movement. syndrome  Severe color,
 dehydratio consistenc
n y, and
quantity of
 Undiagnos stool
ed produced.
abdominal
pain, fever,  Instruct the
vomiting patient to
or nausea. put strips
on the
tongue that
disintegrat
e orally,
allow the
strip to
dissolve,
then drink
lots of
water.

 After the
bowel
check of
the patient,
instruct her
to instruct
him to take
the
medication
12 to 14
hours
before the
operation,
followed
by a simple
liquid diet.

 Advise
patient to
notify a
nurse so
they can
record
signs and
effects of
dietary
 shortages
and
imbalances
in fluids
and
electrolytes
.
Anesthesia/  Stabilizes the  Prevention  Heart  Swelling  Cardiac  Check the
1% neuronal and control of block arrest BP and
Lidocaine membrane pain  (without  Redness heart
pacemaker)  Abnorma monitor
 Inhibiting the  Treatment of  Skin l prior to
ionic fluxes painful Severe irritation heartbeat lidocaine
required for urethritis sinoatrial administrat
the initiation block  Nausea  Methemo ion.
 Anesthetic (without globinem
 Conduction of lubricant for pacemaker)  Vomiting ia  For signs
impulses endotracheal of toxicity,
intubation  Constipati  Seizures assess
on neurologic
 Severe al and
 Low blood allergic respiratory
pressure status
 Malignan frequently.
 Small red t
or purple hyperther  Blood
spots on mia pressure
the skin monitoring
and cardiac
 Tremor monitoring
during
lidocaine
 Headache
therapy
 Dizziness
 + For
symptoms
of toxicity,
assess
neurologic
al and
respiratory
status
regularly.

 +Stop the
infusion
 immediatel
y if signs
of
overdose
appear and
monitor the
patient
closely.
Pitocin  Stimulating  Rh problems  High  redness or  fast,  Before
20 units in contraction of blood irritation at slow, or raising and
the IV bag the uterus.  Maternal pressure. the uneven initiating
diabetes injection heart labour,
 Increased ca site, rate;
 Placenta nurses
lcium increas  Preeclampsia  loss of  excessive
must
previa appetite, bleeding
es control the
contraction  nausea, long after
 near term  Pregnancy  childbirth; fetal heart
of the uterus.  cramping,
rate and
with more
 stomach  headache
than one  confusion uterine
pain,
fetus.  slurred
contraction
 more
intense or speech,
 Fetal more  hallucinat  +Occasion
distress frequent ions, ally, this
contraction  severe medication
 Grand s vomiting, triggers
multiparity  runny  severe w water
. nose, eakness, intoxicatio
 Malpresent  sinus pain  muscle n. Monitor
or irritation cramps, the patient
ation of
fetus.  memory  loss of for signs
problems. coordinati and
on, symptoms
 feeling and, if they
unsteady, occur,
 seizure  contact a
 fainting, doctor or
other
health care
provider.

 +Assess
the
character,
frequency ,
and
duration of
uterine
 contraction
s; uterine
resting
tone; and
frequent
fetal heart
rate during
administrat
ion.

 Monitor
maternal
electrolytes
and water
retention
may result
in
hypochlore
mia or
hyponatre
mia

 Prior to
administrat
ion of
oxytocin
for
induction
of labour,
fetal
growth,
appearance
, and pelvic
adequacy
should be
assessed.